000			03392nam a22006017a 4500
008			191010s20192019 xxu||||| |||| 00| 0 eng d
022			_a2000-6764
024			_a10.1080/2000656X.2019.1650057 [doi]
040			_aOvid MEDLINE(R)
099			_a31478782
245			_aVenous thromboembolism in plastic surgery: the current state of evidence in risk assessment and chemoprophylactic options.
251			_aJournal of Plastic Surgery and Hand Surgery. 53(6):370-380, 2019 Dec.
252			_aJ Plast Surg Hand Surg. 53(6):370-380, 2019 Dec.
252			_zJ Plast Surg Hand Surg. :1-11, 2019 Sep 03
253			_aJournal of plastic surgery and hand surgery
260			_c2019
260			_fFY2020
265			_saheadofprint
265			_sppublish
266			_d2019-10-10
268			_aJournal of Plastic Surgery and Hand Surgery. :1-11, 2019 Sep 03
520			_aThe application of venous thromboembolism (VTE) prophylaxis has been the topic of intense debate in plastic surgery. The overall incidence of VTE is low in plastic surgery patients as compared to other surgical subspecialties but may be higher in the inpatient rather than outpatient plastic surgery populations. The Caprini Risk Assessment Model is the most highly studied and validated tool to assess VTE risk in plastic surgery patients. However, the Caprini model lacks procedure-specific risk assessment and patient-specific risk factor calculations. Due to these limitations, such as the low incidence and the heterogeneous nature of the specialty, trials lacked the power to capture proof of benefit, except in the highest-risk inpatient population. The emerging use of aspirin and novel oral anticoagulants may provide an alternative, as noninferiority in terms of efficacy and safety has been demonstrated in other fields. In this review, the authors intend to summarize the current state of evidence for prevention and explore the modalities available for prophylaxis, including novel oral anticoagulants.
546			_aEnglish
650			_a*Anticoagulants/tu [Therapeutic Use]
650			_a*Chemoprevention
650			_a*Reconstructive Surgical Procedures/ae [Adverse Effects]
650			_a*Risk Assessment
650			_a*Venous Thromboembolism/pc [Prevention & Control]
650			_aAdministration, Oral
650			_aAnticoagulants/pd [Pharmacology]
650			_aAspirin/pd [Pharmacology]
650			_aAspirin/tu [Therapeutic Use]
650			_aHeparin, Low-Molecular-Weight/pd [Pharmacology]
650			_aHeparin, Low-Molecular-Weight/tu [Therapeutic Use]
650			_aHumans
650			_aIncidence
650			_aPostoperative Complications
650			_aPyrazoles/pd [Pharmacology]
650			_aPyrazoles/tu [Therapeutic Use]
650			_aPyridones/pd [Pharmacology]
650			_aPyridones/tu [Therapeutic Use]
650			_aRivaroxaban/pd [Pharmacology]
650			_aRivaroxaban/tu [Therapeutic Use]
651			_aMedStar Health Research Institute
651			_aMedStar Washington Hospital Center
656			_aSurgery/Plastic Surgery
657			_aJournal Article
700			_aBlack, Cara K
700			_aFan, Kenneth L
790			_aAbbate O, Black CK, Camden RC, Evans KK, Fan KL, Lu K
856			_uhttps://dx.doi.org/10.1080/2000656X.2019.1650057 _zhttps://dx.doi.org/10.1080/2000656X.2019.1650057
942			_cART _dArticle
999			_c4601 _d4601